US Stock MarketDetailed Quotes

RDY Dr. Reddy's Laboratories

Watchlist
  • 13.155
  • -0.005-0.04%
Trading Apr 2 10:18 ET
10.96BMarket Cap17.49P/E (TTM)

About Dr. Reddy's Laboratories Company

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment focuses on manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Company Profile

SymbolRDY
Company NameDr. Reddy's Laboratories
Listing DateApr 11, 2001
Issue Price10.04
Founded1984
CEOMr. Erez Israeli
MarketNYSE
Employees27048
Securities TypeDR
ADS Ratio1.0 : 5.0
Fiscal Year Ends03-31
AddressDoor No. 8-2-337,Road No. 3,Banjara Hills
CityHyderabad
ProvinceTelangana
CountryIndia
Zip Code500034
Phone91-40-49002900

Company Executives

  • Name
  • Position
  • Salary
  • Patrick Aghanian
  • Chief Executive Officer, European Generics
  • 63.09M
  • Marc Kikuchi
  • Chief Executive Officer, North America Generics
  • 53.48M
  • M. V. Ramana
  • Chief Executive Officer, Branded Markets, India and Emerging Countries
  • 82.74M
  • Erez Israeli
  • Chief Executive Officer
  • 197.09M
  • Archana Bhaskar
  • Chief Human Resource Officer
  • 65.21M
  • Phani Mitra B
  • Chief Information Officer
  • --
  • Parag Agarwal
  • Chief Financial Officer
  • 64.66M
  • M V Narasimham
  • Deputy Chief Financial Officer
  • 48.82M
  • B Phanimitra
  • Chief Digital and Information Officer
  • 15.13M
  • K. Satish Reddy
  • Co-Chairman of the Board
  • 116.17M
  • G.V. Prasad
  • Co-Chairman of the Board and Managing Director
  • 186.28M
  • Shikha Sanjaya Sharma
  • Independent Director
  • 13.34M
  • Penny Wan
  • Independent Director
  • 17.10M
  • Kalpana Morparia
  • Independent Director
  • 1.67M
  • Sanjiv Mehta
  • Independent Director
  • 3.32M
  • Leo Puri
  • Independent Director
  • 17.10M
  • Arun M. Kumar
  • Independent Director
  • 18.77M
  • Dr. K. P. Krishnan
  • Independent Director
  • 14.18M
  • Dr. Claudio Albrecht
  • Independent Director
  • 16.09M
  • Dr. Alpna Seth, PhD
  • Independent Director
  • 8.25M
  • Sushrut Kulkarni
  • Global Head of Integrated Product Development Organisation
  • 55.63M
  • Sanjay Sharma
  • Global Head of Manufacturing
  • 66.05M
  • Krishna Venkatesh
  • Global Head, Quality and Pharmacovigilance
  • 6.15M
  • Deepak Sapra
  • Global Head of Pharmaceutical Services and Active Ingredients
  • 41.90M
  • Dr. Jayanth Sridhar
  • Global Head of Biologics
  • 34.59M

Market Insights

Warren Buffett Portfolio Warren Buffett Portfolio

Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.

Unlock Now

Discussing

北水爆買!中國資產能否延續漲勢?
3月17日早盤,地產代理、物業服務及管理等板塊漲幅明顯,貝殼-W早盤漲逾4%,碧桂園服務漲逾9%。政策消息面上,兩部門發文落實專項債支持收地,中房協組織民營房企座談會。中國資產本輪火爆行情還能持續多久?你會如何投資? Show More

focus on technology stocks

Top tech company strong as always.